Radiometric and radiotranscriptomic reports in the prostate cancer research field—(such as MRI, PSMA‐PET/CT and ultrasound), combining either with transcriptomic or with prostate‐specific membrane antigen detection, have been developed to improve diagnosis, therapeutics and prognosis of prostate cancer—a comparison. This evidence concerns the gene FOLH1 and Familial prostate cancer.